0 29

Cited 0 times in

Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B

Authors
 Terry Cheuk-Fung Yip  ;  Hye Won Lee  ;  Vincent Wai-Sun Wong  ;  Grace Lai-Hung Wong  ;  Yee-Kit Tse  ;  Grace Chung-Yan Lui  ;  Sang Hoon Ahn  ;  Henry Lik-Yuen Chan 
Citation
 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.35(9) : 1610-1618, 2020-09 
Journal Title
 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 
ISSN
 0815-9319 
Issue Date
2020-09
MeSH
Age Factors ; Aged ; Alanine Transaminase / blood ; Antiviral Agents / therapeutic use* ; Female ; Guanine / analogs & derivatives* ; Guanine / therapeutic use ; Hepatitis B, Chronic / complications ; Hepatitis B, Chronic / drug therapy* ; Hepatitis B, Chronic / mortality* ; Humans ; Liver Cirrhosis / drug therapy ; Liver Cirrhosis / etiology ; Liver Cirrhosis / mortality ; Liver Failure / etiology ; Liver Failure / prevention & control ; Male ; Middle Aged ; Research Design* ; Retrospective Studies ; Serum Albumin ; Survival Rate ; Tenofovir / therapeutic use* ; Treatment Outcome
Keywords
MELD improvement ; liver cirrhosis ; transplant-free survival
Abstract
Background and aims: Improvement in Model for End-Stage Liver Disease (MELD) score during antiviral treatment is associated with reduced hepatic decompensation and death in patients with chronic hepatitis B (CHB)-related cirrhosis. We aimed to identify factors associated with transplant-free survival and on-treatment MELD score improvement. Methods: We identified patients with CHB-related cirrhosis and MELD score ≥ 15 at the start of entecavir and/or tenofovir disoproxil fumarate treatment between 2005 and 2017. The primary endpoint was transplant-free survival at month 6. The secondary endpoints at month 6 were transplant-free survival with > 5-point improvement in MELD score and transplant-free survival with MELD score < 15. Results: Of 999 cirrhotic CHB patients, 605 (60.6%) achieved transplant-free survival at month 6. Proportion of transplant-free survival at month 6 stabilized at 10% in patients with high MELD. Patients who achieved transplant-free survival at month 6 were younger, had lower MELD score, lower alanine aminotransferase (ALT), and higher albumin at baseline. Of 605 patients with transplant-free survival, 276 (45.6%) achieved > 5-point improvement in MELD score; 183 (30.2%) had 1-point to 5-point improvement in MELD score; 146 (24.1%) had no improvement or a worsened MELD score. Also, 321 (53.1%) patients with transplant-free survival had a MELD score < 15 at month 6. Conclusion: On top of lower MELD score, patients with CHB-related cirrhosis who are younger, have higher albumin, and lower ALT are more likely to achieve transplant-free survival after 6 months of antiviral treatment.
Full Text
https://onlinelibrary.wiley.com/doi/10.1111/jgh.15007
DOI
10.1111/jgh.15007
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Hye Won(이혜원) ORCID logo https://orcid.org/0000-0002-3552-3560
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180399
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links